Clinical Trials Browser

spartalizumab × Dermatologic × 30 days × Clear all

NCT06425926 2026-03-27

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Phase 1/2 Recruiting

Melanoma